Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Phase 3

Conditions: Sarcoma

First Posted Date: 2006-09-21

Last Posted Date: 2013-08-12

Lead Sponsor: European Paediatric Soft Tissue Sarcoma Study Group

Target Recruit Count: 600

Registration Number: NCT00379457

Locations: 🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland

and more 23 locations

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 2

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Biological: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Biological: tetanus toxoid helper peptide
Drug: carboplatin
Drug: paclitaxel
Procedure: conventional surgery

First Posted Date: 2006-09-07

Last Posted Date: 2022-09-21

Lead Sponsor: Craig L Slingluff, Jr

Target Recruit Count: 6

Registration Number: NCT00373217

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Phase 2

Withdrawn

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2006-08-30

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00369954

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Phase 2

Terminated

Conditions: Advanced Non-squamous NSCLC

Interventions: Biological: Bevacizumab
Drug: AMG 706
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-08-29

Last Posted Date: 2018-01-04

Lead Sponsor: Amgen

Target Recruit Count: 186

Registration Number: NCT00369070

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Stage II Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: paclitaxel
Biological: bevacizumab
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2014-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00369551

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Phase 1

Terminated

Conditions: Esophageal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Esophageal Cancer

First Posted Date: 2006-08-24

Last Posted Date: 2012-07-16

Lead Sponsor: Stanford University

Target Recruit Count: 4

Registration Number: NCT00368329

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: carboplatin
Drug: paclitaxel
Drug: trastuzumab

First Posted Date: 2006-08-23

Last Posted Date: 2020-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT00367471

Locations: 🇺🇸
Novartis Investigative Site, Greensboro, North Carolina, United States

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

First Posted Date: 2006-08-17

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00365755

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: etoposide
Drug: carboplatin

First Posted Date: 2006-08-15

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 908

Registration Number: NCT00363415

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Phase 1

Completed

Conditions: Brain Tumor
Brain Metastases

Interventions: Drug: carboplatin
Drug: temozolomide

First Posted Date: 2006-08-10

Last Posted Date: 2017-06-01

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00362817

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy